CYTK Cytokinetics, Incorporated
$63.60+2.07%
Last close: · regular session · Last 60 sessions
After-hours $64.00 +0.64% ·
- Float
- 121.1M
- Last filing
- 4 · Nov 3, 2026
Latest SEC filings for CYTK
| 4 | Insider transaction | |
| 4 | Insider transaction | |
| 8-K | Current report | |
| 8-K | Current report | |
| 8-K | Current report | |
| 10-Q | Quarterly report | |
| SCHEDULE 13G/A | ||
| 8-K | Current report | |
| 8-K | Current report | |
| 424B5 | Offering — dilutive |
Dilution today: new offering filings and reverse splits
Float: 121.1M shares. Latest SEC filing: 4 on Nov 3, 2026. CYTK closed at $63.60 (+2.07%) on Nov 4, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for CYTK in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 498
- Website: https://www.cytokinetics.com
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Latest CYTK news
- Cytokinetics outlines >50% new-to-brand share goal by year-end as MYQORZO expands into the U.K. this quarter Read article
- Cytokinetics GAAP EPS of -$1.37 beats by $0.09, revenue of $47.6M beats by $5.26M Read article
- Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy? Read article
- Cytokinetics to Announce Third Quarter Results on November 4, 2026 Read article
- Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026 Read article
Recent dilution filers
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.